Cohort Studyhigh evidence
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
JAMA cardiology·September 16, 2026·PMID 42747817
Why it mattersFrailty is common in patients with cardiovascular disease and obesity, yet clinicians may hesitate to use GLP-1 receptor agonists in frail individuals due to concerns about tolerability or reduced benefit. This analysis provides reassurance that semaglutide's cardiovascular and mortality benefits are consistent regardless of frailty, and that frail patients may experience greater quality-of-life improvements.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled